Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
Aichberger KJ, Mayerhofer M, Gleixner KV, Krauth MT, Gruze A, Pickl WF, Wacheck V, Selzer E, Müllauer L, Agis H, Sillaber C, Valent P. Aichberger KJ, et al. Among authors: wacheck v. Blood. 2007 Apr 1;109(7):3031-41. doi: 10.1182/blood-2006-07-032714. Blood. 2007. PMID: 17110460 Free article.
Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C. Aichberger KJ, et al. Among authors: wacheck v. Blood. 2005 Apr 15;105(8):3303-11. doi: 10.1182/blood-2004-02-0749. Epub 2004 Dec 30. Blood. 2005. PMID: 15626746 Free article.
Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
Thallinger C, Wolschek MF, Maierhofer H, Skvara H, Pehamberger H, Monia BP, Jansen B, Wacheck V, Selzer E. Thallinger C, et al. Among authors: wacheck v. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4185-91. doi: 10.1158/1078-0432.CCR-03-0774. Clin Cancer Res. 2004. PMID: 15217956
The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils.
Blatt K, Herrmann H, Mirkina I, Hadzijusufovic E, Peter B, Strommer S, Hoermann G, Mayerhofer M, Hoetzenecker K, Klepetko W, Ghanim V, Marth K, Füreder T, Wacheck V, Valenta R, Valent P. Blatt K, et al. Among authors: wacheck v. PLoS One. 2012;7(1):e29925. doi: 10.1371/journal.pone.0029925. Epub 2012 Jan 27. PLoS One. 2012. PMID: 22299028 Free PMC article.
Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells.
Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G, Schernthaner GH, Wacheck V, Selzer E, Sperr WR, Valent P. Hauswirth AW, et al. Among authors: wacheck v. Eur J Clin Invest. 2007 Jan;37(1):73-82. doi: 10.1111/j.1365-2362.2007.01746.x. Eur J Clin Invest. 2007. PMID: 17181570
86 results